<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04543162</url>
  </required_header>
  <id_info>
    <org_study_id>RNI 2019 BOUVIER (Biotraumap)</org_study_id>
    <secondary_id>2019-A01228-49</secondary_id>
    <nct_id>NCT04543162</nct_id>
  </id_info>
  <brief_title>Usefulness of Biomarkers in the Management of Mild Traumatic Brain Injury in Adults (Biotraumap)</brief_title>
  <acronym>Biotraumap</acronym>
  <official_title>Usefulness of Biomarkers in the Management of Mild Traumatic Brain Injury in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The indication of cranial computed tomography (CCT) is difficult to define for patients with&#xD;
      mild traumatic brain injury (mTBI). For mTBI patients with a medium risk of intracranial&#xD;
      complications, CCT scans are indicated although 90% of them are normal.&#xD;
&#xD;
      The interest of the S100B protein has been widely demonstrated in the management of mTBI in&#xD;
      adults. Its serum concentration (for blood sampling drawn less than 3 hours after trauma) can&#xD;
      accurately predict a normal CCT scan for mTBI patients with a medium risk of intracranial&#xD;
      complications. That's why, serum assay of the S100B protein is routinely used in the&#xD;
      Emergency Department of Clermont-Ferrand University Hospital for the treatment of patients&#xD;
      with mTBI.&#xD;
&#xD;
      The objective of the study is to optimize the management strategy for mTBI patients by blood&#xD;
      testing of new brain biomarkers. These biomarkers are synthesized by brain cells and are&#xD;
      released into the blood in case of intracranial lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Other biomarkers of brain damage, involved in the pathophysiology of head trauma, are also&#xD;
      known. These are, for example, GFAP (Glial Fibrillary Acidic Protein), UCH-L1 (Ubiquitine&#xD;
      Carboxy Terminal Hydrolase L1), NSE (Neurone Specific Enolase), Tau, SBDP (Spectrin Breakdown&#xD;
      Products) or NFL (Neurofilament) protein. To date, the too limited number of studies doesn't&#xD;
      enable the use of these biomarkers routinely. Therefore we will study the interest of these&#xD;
      biomarkers in the management of adult patients' mTBI. We wish to set a collection of&#xD;
      biological samples drawn from 1500 patients consulting for mTBI (with a medium risk of&#xD;
      intracranial complications) at the Emergency Department of Clermont-Ferrand University&#xD;
      Hospital, and requiring an assay of the S100B protein.&#xD;
&#xD;
      The study will take place over a period of 36 months at Clermont-Ferrand University Hospital.&#xD;
      Patients cared for mTBI when they come to the Emergency Department will be recruited&#xD;
      according to the inclusion criteria. In case of no opposition, when having their blood drawn,&#xD;
      one more tube will be drawn per patient. Then, the obtained serum will be frozen at -80 ° C&#xD;
      for the next assays of the cerebral biomarkers such as: GFAP, UCH-L1, NSE, Tau, SBDP, NFL,&#xD;
      etc. A later 2-weeks' telephone call after the head trauma will be made by a member of the&#xD;
      staff of the Department of Biochemistry and Molecular Genetics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2019</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic value of cerebral biomarkers GFAP</measure>
    <time_frame>Day 0</time_frame>
    <description>Evaluate the diagnostic value of cerebral biomarkers GFAP (ng/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic value of cerebral biomarkers UCH-L1</measure>
    <time_frame>Day 0</time_frame>
    <description>Evaluate the diagnostic value of cerebral biomarkers UCH-L1 (ng/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic value of cerebral biomarkers NSE</measure>
    <time_frame>Day 0</time_frame>
    <description>Evaluate the diagnostic value of cerebral biomarkers NSE (µg/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic value of cerebral biomarkers Tau</measure>
    <time_frame>Day 0</time_frame>
    <description>Evaluate the diagnostic value of cerebral biomarkers TAU (ng/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic value of cerebral biomarkers SBDP</measure>
    <time_frame>Day 0</time_frame>
    <description>Evaluate the diagnostic value of cerebral biomarkers SBDP (µg/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic value of cerebral biomarkers NFL</measure>
    <time_frame>Day 0</time_frame>
    <description>Evaluate the diagnostic value of cerebral biomarkers NFL (ng/L)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Utility of serum biomarker measurement with respect to reduction of the cost of management</measure>
    <time_frame>Day 0</time_frame>
    <description>Calculate this cost reduction compared to the cost of a cerebral tomodensitometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors (antiplatelet agent) on biomarker results</measure>
    <time_frame>Day 0</time_frame>
    <description>Collect information from medical records and assess the impact on biomarker results from statistical tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>risk factors (loss of consciousness) on biomarker results</measure>
    <time_frame>Day 0</time_frame>
    <description>Collect information from medical records and assess the impact on biomarker results from statistical tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>risk factors (amnesia) on biomarker results</measure>
    <time_frame>Day 0</time_frame>
    <description>Collect information from medical records and assess the impact on biomarker results from statistical tests</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <condition>Intracranial Injury</condition>
  <arm_group>
    <arm_group_label>patients with Mild Traumatic Brain Injury</arm_group_label>
    <description>patients with Mild Traumatic Brain Injury</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Collection of additional blood volume (approximately 7 mL) during blood tests provided as&#xD;
      part of the usual medical care in emergencies&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with mild Traumatic Brain Injury&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patient, major&#xD;
&#xD;
          -  Patient admitted to the Emergency Department for mTBI, with a medium risk of&#xD;
             intracranial lesions according to the SFMU (French Emergency Medicine Society)&#xD;
             criteria, for which an S100B protein assay is indicated:&#xD;
&#xD;
          -  GCS score of 15 with at least one associated risk factor: amnesia facts more than 30&#xD;
             minutes before the mTBI loss of consciousness, anti platelet aggregating agent&#xD;
&#xD;
          -  Time between mTBI and blood draw (for the S100B protein assay) less than 3 hours.&#xD;
&#xD;
          -  Patient covered by a Social Security scheme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient classified in the high risk group of intracranial lesions according to SFMU&#xD;
             criteria :&#xD;
&#xD;
          -  GCS score less than 15, 2 hours after the trauma&#xD;
&#xD;
          -  Focused neurological deficit&#xD;
&#xD;
          -  Post-traumatic convulsion&#xD;
&#xD;
          -  Suspicion of open fracture of the skull or embarrassment&#xD;
&#xD;
          -  Any sign of fracture of the base of the skull (hemotympanum, bilateral periorbital&#xD;
             bruise, otorrhea or rhinorrhea of cerebrospinal fluid)&#xD;
&#xD;
          -  Treatment with anticoagulants&#xD;
&#xD;
          -  More than one episode of vomiting.&#xD;
&#xD;
          -  Patient classified in the group at low risk of intracranial lesions according to the&#xD;
             SFMU criteria, presenting a GCS score of 15 without any criteria for moderate or high&#xD;
             risk groups of intracranial lesions.&#xD;
&#xD;
          -  Patient consulting for moderate or severe head trauma (GCS score less than 13).&#xD;
&#xD;
          -  Refusal of the patient (signature of the opposition form).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damien Bouvier</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lise Laclautre</last_name>
    <phone>04 73 75 11 95</phone>
    <email>promo_interne_drci@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien Bouvier</last_name>
      <email>dbouvier@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Damien Bouvier</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeannot Schmidt</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Allouchery G, Moustafa F, Roubin J, Pereira B, Schmidt J, Raconnat J, Pic D, Sapin V, Bouvier D. Clinical validation of S100B in the management of a mild traumatic brain injury: issues from an interventional cohort of 1449 adult patients. Clin Chem Lab Med. 2018 Oct 25;56(11):1897-1904. doi: 10.1515/cclm-2018-0471.</citation>
    <PMID>29924734</PMID>
  </reference>
  <reference>
    <citation>Biberthaler P, Linsenmeier U, Pfeifer KJ, Kroetz M, Mussack T, Kanz KG, Hoecherl EF, Jonas F, Marzi I, Leucht P, Jochum M, Mutschler W. Serum S-100B concentration provides additional information fot the indication of computed tomography in patients after minor head injury: a prospective multicenter study. Shock. 2006 May;25(5):446-53.</citation>
    <PMID>16680008</PMID>
  </reference>
  <reference>
    <citation>Bouvier D, Oddoze C, Ben Haim D, Moustafa F, Legrand A, Alazia M, Jehle E, Schmidt J, Sapin V. [Interest of S100B protein blood level determination for the management of patients with minor head trauma]. Ann Biol Clin (Paris). 2009 Jul-Aug;67(4):425-31. doi: 10.1684/abc.2009.0347. French.</citation>
    <PMID>19654082</PMID>
  </reference>
  <reference>
    <citation>Calcagnile O, Undén L, Undén J. Clinical validation of S100B use in management of mild head injury. BMC Emerg Med. 2012 Oct 27;12:13. doi: 10.1186/1471-227X-12-13.</citation>
    <PMID>23102492</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 26, 2019</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glasgow Coma Scale (GCS) score of 15</keyword>
  <keyword>S100B</keyword>
  <keyword>Mild Traumatic Brain Injury</keyword>
  <keyword>Brain biomarkers</keyword>
  <keyword>Cerebral biomarkers</keyword>
  <keyword>Intracranial lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Brain Concussion</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

